MS Speaks

Multiple Sclerosis => MS - RESEARCH AND NEWS => Topic started by: agate on September 29, 2016, 05:18:38 pm

Title: MS patients may be at lower risk for other illnesses (Danish study)
Post by: agate on September 29, 2016, 05:18:38 pm
From Multiple Sclerosis News Today, September 19--a summary of a paper presented at the ECTRIMS conference (September 14-17, London):

Quote
#ECTRIMS2016 – MS Patients May Be at Lower Risk for Other Illnesses, Danish Study Suggests

Patricia Inacio, PhD

Preliminary results of a study in Danish patients with multiple sclerosis (MS) suggest that inverse comorbidity may exist in the MS population, lowering patients’ risk for other types of diseases. The results were given in an oral presentation, “Inverse comorbidity in multiple sclerosis. Findings in a complete nationwide cohort,” at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in London (Sept. 14-17).

Inverse comorbidity is a concept that defines a lower-than-expected probability of disease (in comparison to the general population) in individuals who have been diagnosed with other medical conditions.

Researchers, in a study financed by the Danish Multiple Sclerosis Society, performed a combined case-control and cohort study using a total nationwide cohort of Danish MS patients, whose clinical disease onset was registered between 1980 and 2005. Each MS case was randomly matched to five healthy individuals (the control group) by gender, year of birth, and municipality on Jan. 1 in the year of MS onset (index date). Following the study population from January 1977 until the index date, and from the index date until December 2012, the team assessed the occurrence of comorbidities (at the individual level) before and after disease onset.

The study included, in total, 8,947 eligible MS cases and 44,735 control cases.

Researchers found a decreased risk for cerebrovascular comorbidity in MS patients when compared to controls before the index date — or date of disease onset — although the findings here didn’t reach the level of statistical significance. After the index date, researchers observed a decrease in the occurrence of chronic lung disease (asthma and chronic obstructive pulmonary disease [COPD]), as well as overall cancer among MS patients. Once again, however, the results did not reach a statistical significance.

Still, findings suggest that MS patients may carry lower risks for cerebrovascular disease before the onset of MS, and a decreased risk for cancers and pulmonary diseases after MS onset, hinting at a trend toward inverse comorbidity in MS patients for certain medical conditions. But the authors state that future studies should confirm this hypothesis.

“Identification of inverse comorbidity and of its underlying mechanisms may provide new important entry points into the understanding of MS,”  the team concluded.

https://multiplesclerosisnewstoday.com/2016/09/19/inverse-comorbidity-in-ms-patients-suggested-in-danish-study?utm_source=Multiple+Sclerosis&utm_campaign=135ee84e5b-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-135ee84e5b-71286581 (https://multiplesclerosisnewstoday.com/2016/09/19/inverse-comorbidity-in-ms-patients-suggested-in-danish-study?utm_source=Multiple+Sclerosis&utm_campaign=135ee84e5b-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-135ee84e5b-71286581)
Title: Re: MS patients may be at lower risk for other illnesses (Danish study)
Post by: ssalimi on September 30, 2016, 10:29:59 am
From Multiple Sclerosis News Today, September 19--a summary of a paper presented at the ECTRIMS conference (September 14-17, London):

Quote
#ECTRIMS2016 – MS Patients May Be at Lower Risk for Other Illnesses, Danish Study Suggests

Patricia Inacio, PhD

Preliminary results of a study in Danish patients with multiple sclerosis (MS) suggest that inverse comorbidity may exist in the MS population, lowering patients’ risk for other types of diseases. The results were given in an oral presentation, “Inverse comorbidity in multiple sclerosis. Findings in a complete nationwide cohort,” at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in London (Sept. 14-17).

Inverse comorbidity is a concept that defines a lower-than-expected probability of disease (in comparison to the general population) in individuals who have been diagnosed with other medical conditions.

Researchers, in a study financed by the Danish Multiple Sclerosis Society, performed a combined case-control and cohort study using a total nationwide cohort of Danish MS patients, whose clinical disease onset was registered between 1980 and 2005. Each MS case was randomly matched to five healthy individuals (the control group) by gender, year of birth, and municipality on Jan. 1 in the year of MS onset (index date). Following the study population from January 1977 until the index date, and from the index date until December 2012, the team assessed the occurrence of comorbidities (at the individual level) before and after disease onset.

The study included, in total, 8,947 eligible MS cases and 44,735 control cases.

Researchers found a decreased risk for cerebrovascular comorbidity in MS patients when compared to controls before the index date — or date of disease onset — although the findings here didn’t reach the level of statistical significance. After the index date, researchers observed a decrease in the occurrence of chronic lung disease (asthma and chronic obstructive pulmonary disease [COPD]), as well as overall cancer among MS patients. Once again, however, the results did not reach a statistical significance.

Still, findings suggest that MS patients may carry lower risks for cerebrovascular disease before the onset of MS, and a decreased risk for cancers and pulmonary diseases after MS onset, hinting at a trend toward inverse comorbidity in MS patients for certain medical conditions. But the authors state that future studies should confirm this hypothesis.

“Identification of inverse comorbidity and of its underlying mechanisms may provide new important entry points into the understanding of MS,”  the team concluded.

https://multiplesclerosisnewstoday.com/2016/09/19/inverse-comorbidity-in-ms-patients-suggested-in-danish-study?utm_source=Multiple+Sclerosis&utm_campaign=135ee84e5b-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-135ee84e5b-71286581 (https://multiplesclerosisnewstoday.com/2016/09/19/inverse-comorbidity-in-ms-patients-suggested-in-danish-study?utm_source=Multiple+Sclerosis&utm_campaign=135ee84e5b-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-135ee84e5b-71286581)

Very interesting. I was trying to do some research the other day on overall cancer prevalence in people with MS due to a lot of the new immunomodulators or immunosuppressants and most of the stuff I found dated back before the introduction of these medications but showed an inverse correlation. This is good that the study goes through 2012 but more up to date data would be useful. I fear that using these immunosuppressants might give rise to something worse than MS. A risk I had to take when deciding to get on the medication.
Title: Re: MS patients may be at lower risk for other illnesses (Danish study)
Post by: agate on September 30, 2016, 12:13:08 pm
You probably know this already but there's a difference between an immunomodulator and an immunosuppressant. Most MS drugs are immunomodulator but a few are immunosuppressants.

I was also concerned about any tinkering with the immune system. Maybe more is known about the immune system than I realize but it still seems to me to be a risky business to play around with it.

On the other hand, what else has anyone come up with for MS?
Title: Re: MS patients may be at lower risk for other illnesses (Danish study)
Post by: ssalimi on September 30, 2016, 03:10:07 pm
You probably know this already but there's a difference between an immunomodulator and an immunosuppressant. Most MS drugs are immunomodulator but a few are immunosuppressants.

I was also concerned about any tinkering with the immune system. Maybe more is known about the immune system than I realize but it still seems to me to be a risky business to play around with it.

On the other hand, what else has anyone come up with for MS?

Agreed. Sad that the decision is based on picking between the lesser of two evils. I think remyelination is the best chance we have at stopping this disease.